This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Kidney Disease
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of chronic kidney disease in adults with and without type-II diabetes.
Regeneron (REGN)/Sanofi's Libtayo Approved for Additional Indications
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.
Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data
by Kinjel Shah
EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.
Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine
by Zacks Equity Research
Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.
Sanofi's (SNY) Aubagio Gets EU Nod for MS in Pediatric Patients
by Zacks Equity Research
The European Commission approves Sanofi's (SNY) Aubagio for the treatment of pediatric patients aged 10 to 17 years with relapsing-remitting multiple sclerosis.
The Zacks Analyst Blog Highlights: Apple, The Home Depot, Sanofi, Applied Materials and CVS Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, The Home Depot, Sanofi, Applied Materials and CVS Health
Top Stock Reports for Apple, Home Depot & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), The Home Depot (HD), and Sanofi (SNY).
RAPT Reports Positive Data From Atopic Dermatitis Study
by Zacks Equity Research
RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.
Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream
by Zacks Equity Research
Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.
Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
by Zacks Equity Research
Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.
Moderna (MRNA) Seeks Approval for COVID-19 Vaccine in Teens
by Zacks Equity Research
Moderna (MRNA) is seeking authorization for conditional use of its COVID-19 vaccine, mRNA-1273, in adolescents in Europe and Canada.
Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity
by Zacks Equity Research
Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.
Regeneron (REGN) Stock Up 3.5% YTD: What's in Store for 2H21?
by Zacks Equity Research
Regeneron's performance so far in the year has been good on the back of a solid product portfolio and an incremental contribution from the antibody cocktail.
Sanofi (SNY) Stops Venglustat Development as Kidney Cyst Drug
by Zacks Equity Research
Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.
Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer
Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study
by Zacks Equity Research
Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.
J&J's (JNJ) Multiple Sclerosis Drug Ponvory Gets EU Approval
by Zacks Equity Research
J&J's (JNJ) oral multiple sclerosis drug, Ponvory, receives approval in Europe after demonstrating superior efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.
Regeneron (REGN)-Sanofi's Libtayo Gets Positive CHMP Opinion
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Libtayo gets positive CHMP opinion for two additional indications.
The Zacks Analyst Blog Highlights: Cisco Systems, Sanofi, Charles Schwab, Target and ConocoPhillips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco Systems, Sanofi, Charles Schwab, Target and ConocoPhillips
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
Top Analyst Reports for Cisco, Sanofi & Charles Schwab
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Sanofi (SNY), and The Charles Schwab Corporation (SCHW).
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
Lilly's (LLY) Fifth Tirzepatide Study Meets All Key Endpoints
by Zacks Equity Research
Lilly's (LLY) SURPASS-4 study evaluating tirzepatide against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk meets all primary and key secondary endpoints.
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
Regeneron (REGN) Resumes Enrollment in Lymphoma Cohorts
by Zacks Equity Research
Regeneron (REGN) resumes enrollment in two patient cohorts of pipeline candidate, odronextamab, a CD20xCD3 bispecific antibody, after the FDA lifts partial clinical hold.